Account
News
09.09.2021
PMA Insights: Week 39 2021

We summarise key pharmaceutical, pricing and market access insights that are worth reading about thi...

Read more
Articles
26.08.2021
NICE remodel plans for January 2022

NICE’s remodel plans focus on delivering faster and fairer access to treatments by optimising appr...

Read more
Articles
28.07.2021
NICEs Highly Specialised Technologies Process

With many anticipated new medicines for rare diseases, countries are beginning to prepare appropriat...

Read more
Articles
05.07.2021
NICE HST program provide faster market access

The HST process is a method for evaluating medicines and treatments specifically indicated for ultra...

Read more
Articles
20.05.2021
What is HST

NICE’s Highly-Specialised Technologies (HST) process is a method for evaluating medicines and trea...

Read more
Articles
28.04.2021
Managed access agreements NICE process

The highly specialised technologies (HST) process was introduced in 2013 for the purpose of evaluati...

Read more
Articles
30.11.2020
Pricing implications for cell and gene therapies

Cell and gene therapies - life saving opportunity for many patients

Read more
Insider Insights
22.02.2020
Recommendations for market access reforms

This resolution includes proposed reforms to the market access (including pricing) landscape designe...

Read more
Publications
06.11.2019
Top 20 most expensive drugs in US

Top 20 most expensive drugs in the US.

Read more
Articles
17.10.2019
An analysis of the top 20 most expensive drugs

This study investigates costs of gene/acute therapies versus chronic treatments for rare diseases, o...

Read more

Stay in the know, subscribe to our newsletter

Be the first to receive exclusive content on the latest from the pharmaceutical and market access sector.